LEMAITRE VASCULAR, INC. Proceeds from Sale and Maturity of Marketable Securities
LEMAITRE VASCULAR, INC. (LMAT) reported Proceeds from Sale and Maturity of Marketable Securities of $212.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-05
- LEMAITRE VASCULAR, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $71.92M.
- LEMAITRE VASCULAR, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $140.57M.
- LEMAITRE VASCULAR, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-06-30 was $0.00.
- LEMAITRE VASCULAR, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-03-31 was $0.00.
- LEMAITRE VASCULAR, INC. proceeds from sale and maturity of marketable securities for fiscal 2025 was $585.07M, a 590.10% increase from fiscal 2024.
- LEMAITRE VASCULAR, INC. proceeds from sale and maturity of marketable securities for fiscal 2024 was $84.78M.
- LEMAITRE VASCULAR, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $0.00.
- LEMAITRE VASCULAR, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $71.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $212.49M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | $140.57M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $585.07M 10-K · filed 2026-02-26 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $84.78M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.00M derived: sum of 2 quarters · filed 2024-02-29 | $3.00M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 | |||
| 2020-12-31 | $4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $4.90M derived: sum of 2 quarters · filed 2023-03-01 | $22.90M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $18.00M 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $18.00M 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $16.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $23.60M derived: sum of 2 quarters · filed 2022-02-28 | $23.60M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $7.00M 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 | |||
| 2018-12-31 | $7.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $20.50M 10-K · filed 2021-03-12 | ||
| 2018-09-30 | $13.00M 10-Q · filed 2018-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |